Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Processing of cyclin E differs between normal and tumor breast cells.

R M Harwell1, D C Porter, C Danes

  • 1Division of Molecular Medicine, Wadsworth Center, Albany, New York 12201-0509, USA.

Cancer Research
|February 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical skills deficiencies and needs of rural general practitioners in South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2018
Same author

PKCiota promotes ovarian tumor progression through deregulation of cyclin E.

Oncogene·2015
Same author

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Oncogene·2014
Same author

Methods for the use of poliovirus vectors for gene delivery.

Methods in molecular medicine·2014
Same author

MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.

Cancer gene therapy·2011
Same author

Resurgence of Morbillivirus infection in Mediterranean dolphins off the French coast.

The Veterinary record·2010
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
See all related articles

Tumor cells process cyclin E into lower molecular weight (LMW) forms, unlike normal cells. This processing increases cyclin E

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncogenesis

Background:

  • Cyclin E is crucial for cell cycle progression (G1 to S-phase).
  • Overexpressed lower molecular weight (LMW) cyclin E isoforms are linked to poor patient prognosis in cancer.
  • Differences in cyclin E processing exist between normal and cancerous cells.

Purpose of the Study:

  • To investigate the mechanisms behind cyclin E processing differences in normal mammary epithelial versus breast cancer cells.
  • To analyze the functional consequences of LMW cyclin E isoforms in tumor cells.

Main Methods:

  • Constructed five N-terminally deleted epitope-tagged (FLAG) cyclin E vectors.
  • Transfected constructs into normal and tumor cell lines.
  • Analyzed protein products using Western blot with FLAG and cyclin E antibodies.

Related Experiment Videos

  • Measured FLAG-associated kinase activity.

    • Main Results:

    • Tumor cells, but not normal cells, processed cyclin E-FLAG constructs into LMW forms.
    • Processing patterns were consistent with endogenous cyclin E in both cell types.
    • LMW cyclin E forms in tumor cells exhibited 10-fold higher kinase activity compared to normal cells.

    Conclusions:

    • Tumor cells possess unique machinery for processing cyclin E into LMW isoforms.
    • Posttranslational modification by a protease likely generates the LMW cyclin E forms prevalent in tumors.
    • These findings highlight a potential mechanism driving oncogenesis and poor patient outcomes.